Drug composition for use in the treatment of diarrhea in animals

Abstract

The invention relates to a drug composition for use in the treatment of diarrhea in animals, comprising a microbial enzyme solution, St. John's wort tea, vitamin B1, vitamin B6 and sodium benzoate as a preservative.

Description

[0001] DRUG COMPOSITION FOR USE IN THE TREATMENT OF DIARRHEA IN ANIMALS

[0002] Technical Field

[0003] The invention relates to a drug composition suitable for use in the treatment of diarrhea in animals.

[0004] State of the Art

[0005] In the present technical field for the treatment of diarrhea occurring in animals, antibiotics and enzymeprobiotics are generally used. For this purpose, it is common to use Bio-Mec Stop branded feed additive premix originating from Japan. Said feed additive premix contains alpha amylase, beta xylanase, beta glucanase, herbal extracts, acetic acid, formic acid, citric acid, propionic acid and protease. There are many components in said product and the cost of production is quite high. It is not known which component functions exactly.

[0006] The documents identified in the patent and literature search for the state of the art are summarized below.

[0007] The patent application with publication number CN111631314 A discloses the use of St. John’s wort for the treatment of diarrhea in animals. However, there is no disclosure that would suggest the use of protease to provide a synergistic effect.

[0008] The patent application with publication number CN 113521260 A mentions compositions for the treatment of various diseases in animals, including diarrhea. Protease, vitamin B, sodium benzoate are mentioned, but there is no St. John’s wort tea ingredient.

[0009] Consequently, due to the above-mentioned drawbacks and the inadequacy of the existing solutions, a development in the related technical field has become necessary.

[0010] Brief Description of the Invention

[0011] The present invention relates to a drug composition suitable for use in the treatment of diarrhea in animals, which meets the above-mentioned requirements, eliminates all disadvantages and brings some additional advantages. The invention is inspired by existing situations and aims to solve the above-mentioned problems.

[0012] The main object of the invention is to develop a new drug composition for treating diarrhea in animals and preventing young mortality. Contrary to the applications in the state of the art, the drug composition subject to the invention does not comprise antibiotics and therefore does not cause side effects. In addition, Sodium Benzoate and St. John’s wort tea, which are not found in the existing products available in the art, are included in the drug composition subject to the invention. Sodium Benzoate naturally increases shelf life and is used instead of antibiotics.

[0013] Another object of the invention is to obtain a new drug composition with a high success rate. Field trials with the drug composition subject to the invention showed a 99% success rate. Although the drug was developed for diarrhea, field trials also showed that the drug has an appetite stimulating effect which is not present in other drugs.

[0014] Another object of the invention is to obtain a new drug composition that, thanks to its natural ingredients, does not cause any side effects.

[0015] According to 2023 TUlK (Turkish Statistical Institute) data, there are approximately 16 million bovine and 52 million ovine animals in Tiirkiye. 40% of these animals are mothers (fertile) and about 90% of these mothers give birth. Of the 5.5 million bovine and 18.5 million ovine that are newborn, at least 10% have diarrhea. According to these data, the potential target population of the drug of the invention is approximately 2.4 million animals.

[0016] The drug composition subject to the invention regulates the intestinal flora by acting on diarrhea and growth retardation, strengthens the immune system and increases appetite. It enables convalescent animals to recover in a short period of time. The drug composition begins to act on the oral mucosa and regulates the flora in the digestive tract. It suppresses pathogenic flora and thus ensures the healthy functioning of the digestive system.

[0017] The drug composition subject to the invention is effective in all diarrhea. However, if it is to be used after or with antibiotic use, it should be supported with an additional 2-3 doses to be effective.

[0018] The drug composition subject to the invention is administered once a day by injecting 10 ml of the drug orally into the sick animal, and the use can be continued with the advice of the veterinarian according to the course of the disease. In the studies carried out within the scope of the invention, approximately 500 drugs were given to veterinarians and animal owners operating in the region and the drugs were tested on calves having diarrhea. Of the approximately 300 drugs for which feedback data were received, over 90% had positive results, while 10% of the calves did not respond to the treatment due to late treatment and concomitant diseases.

[0019] The invention does not use probiotics. Because the probiotic neutralizes the tea mixture. Antibioticcontaining drugs in the state of the art cause a burden on the liver.

[0020] The structural and characteristic features and all advantages of the invention will be more clearly understood by means of the figures given below and the detailed description written with references to these figures, and therefore, the evaluation should be made by considering these figures and the detailed description.

[0021] Detailed Description of the Invention

[0022] In this detailed description, the preferred embodiments of the drug composition subject to the invention are described only for the purpose of a better understanding of the subject matter.

[0023] The invention relates to a drug composition suitable for use in the treatment of diarrhea in animals. The drug composition subject to the invention comprises a microbial enzyme solution, St. John’s wort tea (Hypericum Perforatum L.), vitamin Bl, vitamin B6 (Pyridoxine) and sodium benzoate (E211) as a preservative.

[0024] Said microbial enzyme solution comprises protease enzyme from M. Miehei by controlled fermentation and 15% saline for reconstitution.

[0025] The amounts available for 1 ml of the composition subject to the invention are given below:

[0026] • 0.5 ml microbial enzyme solution,

[0027] • 0.08 ml St. John’s wort tea (Hypericum Perforatum L.),

[0028] • 33 mg vitamin B 1 ,

[0029] • 3 mg vitamin B6 (Pyridoxine),

[0030] • 1 mg preservative sodium benzoate (E211).

[0031] In the studies carried out within the scope of the invention, it was observed that the microbial enzyme solution (protease enzyme type) in the composition provides a synergistic effect. Salt solution increases the success rate due to its ability to retain water in the body. If it is not used, the success rate decreases from 90% to less than 50%.

[0032] In the invention, the oil of St. John’s wort tea is separated and the active ingredient thereof is used. In the trials, it was found that this oil had a negative effect in the case of diarrhea. In the invention, St. John’s wort tea is used by brewing. In the production process of the drug composition subject to the invention, preferably 100 g of St. John’s wort plant is brewed in 1 liter of distilled water, and the branches and leaves of the plant are brewed and filtered preferably at a temperature of 40 °C for 1.5 hours. After the filtration process step, it is boiled for disinfection purposes.

[0033] The invention works thanks to the benefit of St. John’s wort variety for intestinal inflammations and wounds.

[0034] The preferred content of the composition subject to the invention used as a drug for calf and lamb diarrhea for 300 ml of the final product is given below:

[0035] • 100 ml B Complex (100 mg Vitamin Bl, 10 mg Vitamin B6)

[0036] • 176 ml second-class rennet from Mayasan or Super Yeast.

[0037] • St. John’s wort tea (100 g Hypericum Perforatum L. is brewed in 1 liter of water at a temperature of 80° C for 20 minutes, boiled at a temperature of 100 ° C after filtering, then cooled to 15-20 ° C and added to 24 ml mixture).

[0038] All rates have a ± 10% preparation interval.

[0039] There is no improvement in the general condition in animals with vitamin B deficiency. If the yeast group is not added, the diarrhea treatment is delayed. In cases where St. John’s wort tea is not added, blood particles are seen in the stool. In case of these deficiencies, the success rate in diarrhea treatment does not exceed 50%. The success rate of the mixture in the correct ratio is 90%.

[0040] The drug composition subject to the invention is preferably used in 10 ml packages.

Claims

CLAIMS1. A drug composition for use in the treatment of diarrhea in animals, characterized in that it comprises a microbial enzyme solution, St. John’s wort tea, vitamin Bl, vitamin B6 and sodium benzoate as a preservative.

2. The drug composition according to claim 1, characterized in that said microbial enzyme solution comprises protease enzyme and 15% saline for reconstitution.

3. The drug composition according to claim 1, characterized in that said drug composition comprises the following in an amount of 1 ml; o 0.5 ml microbial enzyme solution, o 0.08 ml St. John’s wort tea (Hypericum Perforatum L.), o 33 mg vitamin B 1 , o 3 mg vitamin B6 (Pyridoxine), o 1 mg sodium benzoate as a preservative.

4. The drug composition according to claim 1, characterized in that it comprises second-class rennet.